PEP-Therapy

PEP-Therapy is a IND-stage medical biotechnology company developing peptides as targeted therapies for severe diseases, with an initial focus on oncology.

Year of creation: 2014

Line of business: Biotechnology

Institut Curie: Behind the technology and R&D partner

TECHNOLOGY

PEP-Therapy has developed a proprietary Cell Penetrating and Interfering Peptides (CP&IP) technology for the development of its therapeutic products. These innovative peptides penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Two major innovations have been combined in a single bi-functional peptide to target efficiently and accurately key cellular mechanisms involved in pathologies:

• Optimized Cell Penetrating Peptides (CPP), as a "shuttle" to deliver drugs pharmaceutically active peptides into the cell and also into specific organelles;

• Short Interfering peptides specifically designed to target relevant protein/protein interactions, thus blocking key mechanisms of diseases, with no effect on other physiological functions of the two proteins.

The company's lead product and first CP&IP-based product, PEP-010, is an anti-cancer agent and is entering Phase Ia/b clinical trial in Q1 2021 in partnership with two leading European cancer hospitals, Institut Curie and Gustave Roussy.

APPLICATIONS

Oncology & other severe diseases.

More about PEP-Therapy:

• PEP-Therapy raises €1.2 M to advance its therapeutic peptides

• PEP-Therapy, Institut Curie and Gustave Roussy obtain 2,9 M€ to develop a novel peptide in oncology

• Institut Curie & PEP-Therapy initiate a phase I clinical trial for the treatment of advanced solid tumors

• PEP-Therapy raises €2.75 million in Series A to advance its lead candidate into the clinic

• PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate PEP-010